Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome

Lawrence, Nicholas F.; Hammond, Marc R.; Frederick, Dennie T.; Su, Yongxuan; Dias‐Santagata, Dora; Deng, April; Ma, Sisi; Mahalingam, Meera; Flaherty, Keith T.; Hoang, Mai P.

doi:10.1016/j.jaad.2016.04.059

Cited by 19 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dermoscopy and reflectance confocal microscopy are useful tools for the identification of DM, though immunohistochemical panels are needed for the final diagnosis (18,19). The diagnostic criteria of DM have become more consistent, and the misdiagnosis of DM has decreased in patients (2,20). However, due to the rarity of DM, its clinical and prognostic characteristics have yet to be completely elucidated.…”

Section: Discussionmentioning

confidence: 99%

Desmoplastic melanoma: Demographic and clinicopathological features and disease‑specific prognostic factors

Shi

Xin

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Desmoplastic melanoma (DM) is a rare morphological subtype of melanoma that remains uncharacterized. The aim of the present study was to investigate the incidence of DM, its general demographics, clinicopathological features and disease-specific prognostic factors. DM cases were sampled from the Surveillance, Epidemiology and End Results (SEER) program from between 1973 and 2017. A total of 3,657 cases (median age, 68 years) were identified. The results indicated that DM primarily occurred in Caucasian subjects, with a male-to-female ratio of 2:1. Statistically significant overall survival (OS) and disease-specific survival (DSS) rate differences were identified according to sex, age, treatment, T stage, N stage and SEER historic tumor stage (P<0.05). In multivariate Cox regression analysis, age >68 years, male sex, American Joint Committee on Cancer (AJCC) stage II and III, and SEER historic tumor stage of the regional tumor were all factors associated with poorer OS and DSS rates. The findings also revealed that surgical treatment was associated with favorable DSS and OS rates. In conclusion, DM occurred primarily in Caucasian subjects of 60–80 years of age, with predominance in males. Furthermore, age, sex, AJCC stage, SEER historic tumor stage and surgical treatment were identified as independent prognostic factors of DM in terms of DSS and OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Desmoplastic melanoma: Demographic and clinicopathological features and disease‑specific prognostic factors

Shi

Xin

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The transcription of p53, as well as mRNA splicing and translation is regulated, the mRNA splicing prompts the p53 gene to express several isomeric molecules which have various activities (28). p53 has extremely short half-life in normal cells, which is only 5–30 min.…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway

et al. 2017

View full text Add to dashboard Cite

In the present study, we analyzed the role of microRNA-194 circulating regulated human melanoma cell growth. We found that microRNA-194 expression was markedly suppressed in human melanoma patients, compared with negative control group. Next, disease-free survival (DFS) and overall survival (OS) of high expression in human melanoma patients was higher than those of low expression in human melanoma patients. MicroRNA-194 overexpression inhibited cell proliferation, induced apoptosis, increased caspase-3/−9 activities and promoted Bax/Bcl-2 of human melanoma cells. Furthermore, microRNA-194 overexpression also suppressed PI3K/AKT/FoxO3a signaling pathway and induced p53/p21 signaling pathway. PI3K inhibitor, suppressed PI3K, phosphorylation-AKT, FoxO3a protein expression and increased the effects of microRNA-194 overexpression on cell growth, apoptosis, caspase-3/−9 activities and Bax/Bcl-2 protein expression of human melanoma cells through the induction of p53/p21 signaling pathway. Taken together, these data indicate that circulating microRNA-194 regulated human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.

show abstract

“…Some studies have shown that Ki-67 is one of the prognostic indices of multiple solid tumors, such as nasopharyngeal carcinoma (8), stage I non-small cell lung cancer (9), gastrointestinal stromal tumour (10), and gliomas (11), resected triple-negative breast cancer (12), colorectal cancer (13), hepatocellular carcinoma (14), and thyroid cancer (15). Previous studies have shown an association between Ki-67 expression and melanoma patient prognosis, but the results have been contradictory (16)(17)(18)(19)(20)(21)(22)(23)(24)(25). Some studies show that high Ki-67 expression is an indicator of worse prognosis (16)(17)(18)(19)(20)(21)(22)25), while other studies suggest that high Ki-67 expression predicts favorable prognosis (23,24).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

BackgroundThe prognostic and clinicopathological value of Ki-67 in melanoma is controversial. The purpose of this meta-analysis was to determine the prognostic role of Ki-67 in melanoma patients.Materials and MethodsThe PubMed, Cochrane Library, Web of Science, and Embase databases were searched systematically up to April 9, 2021. We calculated the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the relationship between Ki-67 overexpression and survival outcomes. We also calculated the combined odds ratios (ORs) and 95% CIs to determine the relationship between Ki-67 expression levels and clinicopathologic parameters. All data were statistically analyzed by Stata 11.0.ResultsA total of 10 studies involving 929 patients were included in our meta-analysis. The pooled HR showed that Ki-67 overexpression was connected with poor overall survival rates (HR=2.92, 95% CI=2.17-3.91, p<0.000). However, there was no correlation between Ki-67 overexpression and the PFS (HR=0.999, 95% CI =0.958-1.041, P =0.958; I2 = 21.80%, P =0.258) or RFS (HR=1.14, 95% CI = 0.42-3.11, P =0.993; I2 = 85.00%, P =0.01) rates. Ki-67 expression levels were associated with tumor thickness, but not sex, location, ulceration or vascular invasion.ConclusionKi-67 is a useful poor prognostic indicator for melanoma patients.

show abstract

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome

Cited by 19 publications

References 33 publications

Desmoplastic melanoma: Demographic and clinicopathological features and disease‑specific prognostic factors

Desmoplastic melanoma: Demographic and clinicopathological features and disease‑specific prognostic factors

Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway

Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis

Contact Info

Product

Resources

About